ReviewJournal of clinical medicine2022

Comparison of Efficacy and Safety of Brigatinib in First-Line Treatments for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Systematic Review and Indirect Treatment Comparison.

Yongfeng Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.